

## **BIOSKETCH**

**Sérgio Jerónimo Rodrigues Dias, PhD**

**Date and Place of Birth:** 6 January 1971, Lisboa, Portugal

### **Education**

- Licenciatura in Biology, University of Lisbon (Faculty of Sciences), 1/90-7/94
- PhD in Tumor Immunology, Imperial Cancer Research Fund/University College London, UK, 6/95-12/98

### **Professional Training/Appointments**

- Research Associate, Tropical Medicine, Institute of Tropical Higiene and Medicine of Lisbon, 1/94-12/94
- Research Associate, Tumor Immunology, Imperial Cancer Research Fund, London, 1/95-7/95
- PhD Student, Tumor Immunology, Imperial Cancer Research Fund, London, 7/95-12/98
- Post-doctoral Fellow, Hematology/Oncology Division, Cornell University Medical College, New York, 2/99-12/01.
- Group leader (of the Angiogenesis Laboratory), Centro de Investigação em Patobiologia Molecular(CIPM)/Portuguese Institute of Oncology (IPOFG) and Instituto Gulbenkian Ciência, Lisbon, 12/01-present.
- Principal Investigator and Director of CIPM/IPOFG. 02/04-present.

### **Selected Publications (of a total of 44)**

- Dias S, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. *Journal of Clinical Investigation*, 106: 511-521 (2000).
- Dias S, et al. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. *Proc Natl Acad Sci (PNAS)*, 98(19):10857-62 (2001).
- Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. *Nature Medicine*, 7(11):1194-201 (2001).

- Dias S, et al. VEGF-C signaling through Flt-4 (VEGFR-3) Mediates Leukemic cell proliferation and survival. *Blood*, 99: 2179-2184 (2002).
- Dias S, et al. VEGF promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression. *Blood*, 99(7):2532-40 (2002).
- Heissig B, Hattori K, Dias S et al. Recruitment of Stem and Progenitor Cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. *Cell*, 109(5):625-37 (2002).
- Hattori K, Heissig B, Wu Y, Dias S, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. *Nature Medicine*, 8(8): 841-49 (2002).
- Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, Dias S, et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. *Cancer Cell*. 3(2):131-43 (2003).
- Constantino Rosa Santos S and Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia. *Blood*. 103(10): 3883-9 (2004).
- Fragoso R, Pereira T, Wu Y, Zhu Z, Cabeçadas J and Dias S. VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. *Blood*, 15;107(4):1608-16 (2006).
- Casalou C, Fragoso R, Moura Nunes J and Dias S. VEGF/PLGF induces leukemia cell migration via P38/ERK1/2 kinase pathway, resulting in Rho GTPases activation and caveolae formation. *Leukemia*. 21: 1590-1594 (2007).
- Santos SCR et al. VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. *Experimental Cell Research*. 313(8):1561-1574 (2007)
- Igreja C et al. Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitors in lymphoma patients. *Haematologica-The Hematology Journal*. 92(4):469-77 (2007).
- Igreja C et al. Detailed Molecular characterization of cord blood derived Endothelial Progenitors. *Experimental Hematology*, 36(2):193-203 (2008).

- Caiado F, Real C, Carvalho T, Dias S. Notch pathway modulation on bone marrow-derived vascular precursor cells regulates their angiogenic and wound healing potential. PLoS ONE. 2008;3(11):e3752. Epub 2008 Nov 18.
- MicroRNA expression profiling in bone marrow: implications in hematological malignancies. Costa A, Osório C, Dias S. Biotechnol J. 2009 Jan;4(1):88-97.

### **Personal References**

Professor Frances Balkwill

CRUK/ICRF Translational Oncology Laboratory

St Bartholomew's and The Royal London School of Medicine and Dentistry, 3rd Floor  
Science Building, Charterhouse Square. London EC1M 6BQ, UK

Dr. Shahin Rafii

Department of Genetic Medicine and Division of Hematology and Oncology, Howard  
Hughes Medical Institute, Weill Medical College of Cornell University, New York, New  
York 10021, USA